Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;29(4):783-7.
doi: 10.1038/leu.2014.247. Epub 2014 Aug 20.

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

S Kamel  1 , L Horton  1 , L Ysebaert  2 , M Levade  3 , K Burbury  4 , S Tan  1 , M Cole-Sinclair  1 , J Reynolds  5 , R Filshie  1 , S Schischka  1 , A Khot  4 , S Sandhu  4 , M J Keating  6 , H Nandurkar  7 , C S Tam  8
Affiliations

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

S Kamel et al. Leukemia. 2015 Apr.

Abstract

The BTK (Bruton's tyrosine kinase) inhibitor ibrutinib is associated with an increased risk of bleeding. A previous study reported defects in collagen- and adenosine diphosphate (ADP)-dependent platelet responses when ibrutinib was added ex vivo to patient samples. Whereas the collagen defect is expected given the central role of BTK in glycoprotein VI signaling, the ADP defect lacks a mechanistic explanation. In order to determine the real-life consequences of BTK platelet blockade, we performed light transmission aggregometry in 23 patients receiving ibrutinib treatment. All patients had reductions in collagen-mediated platelet aggregation, with a significant association between the degree of inhibition and the occurrence of clinical bleeding or bruising (P=0.044). This collagen defect was reversible on drug cessation. In contrast to the previous ex vivo report, we found no in vivo ADP defects in subjects receiving standard doses of ibrutinib. These results establish platelet light transmission aggregometry as a method for gauging, at least qualitatively, the severity of platelet impairment in patients receiving ibrutinib treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blood. 2003 Nov 15;102(10):3592-9 - PubMed
    1. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80 - PubMed
    1. Blood. 2009 Aug 27;114(9):1884-92 - PubMed
    1. N Engl J Med. 2013 Sep 26;369(13):1277-8 - PubMed
    1. N Engl J Med. 2013 Jul 4;369(1):32-42 - PubMed

Publication types

MeSH terms